C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719...

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Inflammation Biomarkers

Background:

• Metabolic syndrome is a cluster of conditions including obesity, dyslipidemia, hypertension, and abnormal glucose.
• These metabolic syndrome components are linked to elevated C-reactive protein (CRP) levels.
• CRP is a key marker of inflammation associated with increased cardiovascular risk.

Purpose of the Study:

• To investigate the relationship between CRP levels, metabolic syndrome, and the incidence of cardiovascular events.
• To determine if CRP measurement adds prognostic value to the metabolic syndrome in predicting future cardiovascular risk.

Main Methods:

• Prospective cohort study of 14,719 apparently healthy women followed for 8 years.
• Cardiovascular events included myocardial infarction, stroke, coronary revascularization, or cardiovascular death.
• Analysis assessed interrelationships between baseline CRP, metabolic syndrome characteristics, and event-free survival.

Main Results:

• 24% of women had metabolic syndrome at baseline; CRP levels increased with more metabolic syndrome characteristics.
• CRP levels above 3.0 mg/L showed similar prognostic value for cardiovascular events as having 3+ metabolic syndrome criteria.
• CRP provided additional prognostic information across all metabolic syndrome severity levels, including those with 4-5 characteristics.

Conclusions:

• Measurement of CRP offers clinically significant prognostic information beyond the metabolic syndrome alone.
• CRP can enhance the identification and management of individuals at high risk for cardiovascular events.
• These findings support the routine use of CRP in cardiovascular risk assessment for patients with metabolic syndrome.